Get the Stockscreener App
1.349
0.81%
-0.011
After Hours:
1.31
-0.039
-2.89%
Renovorx Inc stock is traded at $1.349, with a volume of 31,924.
It is down -0.81% in the last 24 hours and down -2.95% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.36
Open:
$1.39
24h Volume:
31,924
Relative Volume:
0.38
Market Cap:
$31.92M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-2.3667
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
-2.25%
1M Performance:
-2.95%
6M Performance:
+4.57%
1Y Performance:
+1.43%
1-Day Range:
$1.32
$1.40
1-Week Range:
$1.315
$1.50
52-Week Range:
$0.7736
$1.86
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
333 W. SANTA CLARA STREET, SUITE 900, SAN JOSE
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.349 | 31.92M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Renovorx Inc Stock (RNXT) Latest News
ASCO GI: RenovoRX’s TAMP system reduces side effects in pancreatic cancer - Yahoo Finance
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 - Business Wire
Analysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before Long - Yahoo Finance
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - PR Newswire
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Renovorx Inc (RNXT-Q) QuotePress Release - The Globe and Mail
Geode Capital Management LLC Grows Stock Holdings in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 - BioSpace
RenovoRx's Cancer Treatment Platform Featured in Three Major Medical Conferences, Phase III Trial Update - StockTitan
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform - Business Wire
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options - Informazione.it
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
RenovoRx Expands Phase III Pancreatic Cancer Trial to Major Research Network, Accelerating Patient Enrollment - StockTitan
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET - Markets Insider
RenovoRx to Host Fireside Chat on Phase III Cancer Trial Progress and 2025 Strategic Outlook - StockTitan
RenovoRx begins commercialisation of RenovoCath device - Yahoo Finance
RenovoRx begins RenovoCath device sales, eyes market expansion By Investing.com - Investing.com Canada
RenovoRx begins RenovoCath device sales, eyes market expansion - Investing.com India
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System - Markets Insider
Eupraxia Pharmaceuticals Inc (EPRX-Q) QuotePress Release - The Globe and Mail
RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial - TipRanks
RenovoRx Expands Phase III Pancreatic Cancer Trial with Major Cancer Institute Partnership | RNXT Stock News - StockTitan
Peripheral IV Catheters Market: Rapid Global Data Volume Growth - openPR
RenovoRx reports Q3 net loss $2.5M vs $1.4M last year - TipRanks
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights - The Manila Times
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully - Simply Wall St
RenovoRx (NASDAQ:RNXT) Stock Price Up 2.5% – Still a Buy? - Defense World
RenovoRx ramps up production of RenovoCath system By Investing.com - Investing.com Australia
RenovoRx ramps up production of RenovoCath system - Investing.com
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians - GlobeNewswire
Rhumbline Advisers Has $1.23 Million Stock Holdings in The RMR Group Inc. (NASDAQ:RMR) - Defense World
Renovos Biologics Appoints New Non-Executive Director - European Pharmaceutical Manufacturer
RXO Inc (RXO) Shares Up 4.51% on Sep 19 - GuruFocus.com
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer - StockTitan
State of New Jersey Common Pension Fund D Has $2.48 Million Stock Position in RXO, Inc. (NYSE:RXO) - Defense World
Jefferies initates Ralph Lauren Corp (RL) stock to a Buy - Knox Daily
Reckitt shares up on report of potential homecare asset sale By Investing.com - Investing.com Australia
Reckitt starts talks on $7.9 bln homecare assets sale, Bloomberg News reports - XM
Federated Hermes Inc. Boosts Stock Position in The RMR Group Inc. (NASDAQ:RMR) - Defense World
Ascendiant Capital Markets Increases RenovoRx (NASDAQ:RNXT) Price Target to $8.25 - Defense World
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
RenovoRx (NASDAQ:RNXT) Trading Up 1.7% - Defense World
What was RenovoRx Inc (RNXT)’s performance in the last session? - US Post News
The time has not yet come to remove your chips from the table: RenovoRx Inc (RNXT) - SETE News
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York - StockTitan
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024 - MSN
RenovoRx (NASDAQ:RNXT) Releases Quarterly Earnings Results - Defense World
RenovoRx continues drug-device combo Phase III trial in pancreatic cancer - Yahoo Finance
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - StockTitan
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):